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PAtherosclerosis
xidized Low-Density Lipoprotein in Children
ith Familial Hypercholesterolemia and Unaffected Siblings
ffect of Pravastatin
essica Rodenburg, MD,* Maud N. Vissers, PHD,* Albert Wiegman, MD, PHD,† Elizabeth R. Miller, BS,‡
aul M. Ridker, PHD, MD, FACC,§ Joseph L. Witztum, MD,‡ John J. P. Kastelein, PHD, MD,*
otirios Tsimikas, MD, FACC‡
msterdam, the Netherlands; San Diego, California; and Boston, Massachusetts
OBJECTIVES To assess the role of oxidized phospholipids (OxPLs) in children with familial hypercholes-
terolemia (FH) and the effect of pravastatin.
BACKGROUND Oxidized phospholipids are a major component of oxidized low-density lipoprotein
(OxLDL) and are bound to lipoprotein (a) [Lp(a)]. The significance of OxPL markers in
children is unknown.
METHODS Children with FH were randomized to placebo (n  88) or pravastatin (n  90) after
instruction on American Heart Association step II diet. Unaffected siblings (n  78) served
as controls. The OxPL content on apolipoprotein B-100 (apoB) detected by antibody E06
(OxPL/apoB ratio), immunoglobulin (Ig)G and IgM immune complexes per apoB (IC/
apoB) and on all apoB particles (total apoB-IC IC/apoB multiplied by plasma apoB levels),
autoantibodies to malondialdehyde (MDA)–low-density lipoprotein (LDL), Lp(a), and apoB
levels were measured at baseline and after two years of treatment.
RESULTS Compared with unaffected siblings, children with FH had significantly lower levels of
OxPL/apoB but higher levels of IgG and IgM total apoB-IC and IgM MDA-LDL
autoantibodies. From baseline to two-year follow-up, compared with placebo pravastatin
treatment resulted in a greater mean percentage change in apoB (18.7% vs. 0.3%; p 
0.001), total IgG apoB-IC (31.9% vs. 12.2%; p  0.001), and total IgM apoB-IC
(25.5% vs. 13.2%; p 0.001). Interestingly, pravastatin also resulted in higher OxPL/apoB
(48.7% vs. 29.3%; p  0.028) and Lp(a) levels (21.9% vs. 10.7%; p  0.044).
CONCLUSIONS Compared with unaffected siblings, children with FH are characterized by elevated levels of
apoB-IC and IgM MDA-LDL autoantibodies. Compared with placebo, pravastatin led to a
greater reduction in apoB-IC but also to a greater increase in OxPL/apoB and Lp(a), which
may represent a novel mechanism of mobilization and clearance of OxPL. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.047Cardiol 2006;47:1803–10) © 2006 by the American College of Cardiology Foundation
c
t
s
a
l
s
a
d
p
a
k
p
m
p
s
M
Shildren with heterozygous familial hypercholesterolemia
FH) are characterized by severely elevated low-density li-
oprotein cholesterol (LDL-C) levels that predispose to the
arly initiation of atherogenesis and premature cardiovascular
isease (CVD). Although most children with this disorder are
symptomatic, they do manifest subclinical atherosclerosis,
uch as impaired endothelial dysfunction and increased intima-
edia thickness (IMT) (1–4). Carotid IMT is considered a
alid surrogate marker for atherosclerosis and therefore em-
loyed to assess atherosclerosis in children with FH. We
reviously showed that pravastatin therapy induced a signifi-
From the Departments of *Vascular Medicine and †Paediatrics, Academic Medical
enter, University of Amsterdam, Amsterdam, the Netherlands; ‡Department of
edicine, University of California, San Diego, California; and the §Center for
ardiovascular Disease Prevention and Department of Medicine, Harvard Medical
chool, Boston, Massachusetts. A patent has been awarded to the University of
alifornia in Dr. Witztum and colleagues’ names for the potential use of the E06
ntibody. The patent was licensed by the University of California to Atherogenics.
r. Witztum is a consultant to Atherogenics. This investigation was supported by
HLBI grant HL56989 to the La Jolla Specialized Center of Research in Molecular
edicine and Atherosclerosis and the Donald W. Reynolds Foundation. Dr. Alan
ogelman acted as the Guest Editor for this paper.d
Manuscript received August 4, 2005; revised manuscript received October 24,
005, accepted December 12, 2005.ant regression of carotid IMT in children with FH compared
o placebo (4).
A wealth of experimental and recently derived clinical data
uggest that lipoprotein oxidation plays an important role in
therogenesis(5). Importantly, circulating oxidized low-density
ipoproteins (OxLDLs) are associated with subclinical athero-
clerosis in adults (6,7) angiographically determined coronary
rtery disease (8), symptomatic CVD, acute coronary syn-
romes (ACS), and vulnerable plaques (7,9–13) and may also
redict acute myocardial infarction (7,14).
The role of circulating OxLDL in the pathogenesis of early
therosclerosis in children and the effect of statins are un-
nown. In the current study, we investigated the effect of
ravastatin on plasma levels of several direct and indirect
arkers of OxLDL in a cohort of FH children, treated with
ravastatin or placebo, as well as in a group of unaffected
iblings.
ETHODS
tudy population and design. We previously performed a
ouble-blind randomized placebo-controlled trial to deter-
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Oxidized LDL in Children Treated With Statins May 2, 2006:1803–10ine the 2-year efficacy and safety of pravastatin versus
lacebo in 214 children age 8 to 18 years with heterozygous
H (4). Children younger than 14 years received 20 mg
ravastatin, and those age 14 years or older received 40 mg
ravastatin daily. Children were also instructed to assume or
ontinue a low-fat diet (ingesting 32.6% total fat and 12.1%
aturated fat after counseling on an American Heart Asso-
iation step II diet) and to maintain habitual physical
ctivity during the intervention period. In addition, relevant
nformation was assembled for 80 unaffected siblings in
hom FH was definitely excluded by deoxyribonucleic acid
nalysis. Carotid intima-media thickness (IMT) was deter-
ined as previously described (1,3,4).
ipids, lipoproteins, and C-reactive protein. From the
riginal cohort, plasma samples from 178 FH children at
aseline and at 2 years and from 78 unaffected siblings at a
ingle time point were available for OxLDL measurements.
lasma levels of cholesterol and triglycerides were deter-
ined by standardized enzymatic procedures as previously
escribed (4). Lipoprotein (a) [Lp(a)] concentrations were
etermined using chemiluminescent enzyme-linked immu-
osorbent assay (ELISA) as previously described (15).
igh-sensitivity C-reactive protein (hsCRP) was measured
y latex-enhanced nephelometry (Dade Behring, Newark,
elaware).
etermination of oxidized phospholipid (OxPL)/
polipoprotein B-100 (apoB) levels, apoB-immune com-
lexes, and malondialdehyde (MDA)-LDL autoantibody
iters. Chemiluminescent ELISA was used to measure
lasma titers of IgG and IgM apoB-immune complexes
IC), and IgG and IgM MDA-LDL (1:200 plasma dilu-
ion) autoantibodies were measured as previously described
16). Each sample was assayed in triplicate, and data are
xpressed as relative light units (RLU) in 100 ms. The
ontent of OxPLs per apoB particle was determined using
he murine monoclonal antibody E06 (OxLDL-E06),
hich specifically binds to the phosphocholine head group
f oxidized but not native phospholipids (13,15,16). A 1:50
ilution of plasma in phosphate-buffered saline is added to
icrotiter wells coated with the monoclonal antibody
B47, which specifically binds apoB particles. Under these
Abbreviations and Acronyms
ACS  acute coronary syndrome
apoB  apolipoprotein B-100
CVD  cardiovascular disease
FH  familial hypercholesterolemia
IC  immune complexes
Ig  immunoglobulin
IMT  intima-media thickness
LDL-C  low-density lipoprotein cholesterol
Lp(a)  lipoprotein (a)
MDA  malondialdehyde
OxLDL  oxidized low-density lipoprotein
OxPL  oxidized phospholipidonditions, a saturating amount of apoB is added to each cell and consequently an equal number of apoB particles are
aptured in each well for all assays. The content of OxPL
er apoB is then determined with biotinylated E06 as
reviously described (13,15,16). Because the amount of
poB bound to each plate is essentially identical for each
lasma sample, we arbitrarily assigned the apoB RLU value
n the denominator as 1 and report the OxPL/apoB values
s OxPL RLU counts only.
The data for apoB-IC are presented in two ways: 1) as
C/apoB, which specifically quantifies the content of
poB-IC on each captured apoB particle; and 2) as total
poB-IC, which reflects the apoB-IC content on all apoB-
ontaining particles in plasma, by multiplying the plasma
C/apoB value by the plasma apoB levels measured inde-
endently. We have previously also reported total levels of
poB-OxPL (16), derived by multiplying the OxPL/apoB
atio by plasma levels of apoB, in patients treated with
tatins. Because of the difficulty in determining the exact
mount of OxPL on non–Lp(a)-apoB lipoproteins versus
n Lp(a), this parameter may not completely reflect the
lasma levels of apoB-associated OxPL. Therefore it is not
eported here pending further validation.
To assess the stability of frozen samples, we repeated all
f the OxLDL measures on the same samples 6 months
fter the initial determination in a second freeze-thaw cycle
nd in a subset of samples at 8 months in a third freeze-thaw
ycle. The data are remarkably consistent, with little vari-
bility (correlation coefficients [r value] between first and
econd run: OxPL/apoB 0.93, MDA-LDL IgG 0.96,
DA-LDL IgM 0.96, apoB-IC IgG 0.96, and apoB-IC
gM 0.81).
tatistical analysis. In the FH group, mean values between
he pravastatin group and the placebo group were compared
sing an independent-sample t test. Chi-square tests were
pplied for comparing distributions of dichotomous data
etween these groups. Differences in baseline characteristics
nd OxLDL markers between FH children and healthy
iblings were analyzed using linear or logistic regression
nalyses. Because some of these children were from the same
amily, these analyses were performed with generalized esti-
ating equations in the Statistical Analyses System (SAS
nstitute, Cary, North Carolina) procedure GENMOD to
ccount for correlations within families. In a stepwise multi-
ariate analysis, we adjusted for potential confounders.
The effect of pravastatin on OxLDL markers, apoB, and
p(a) levels was studied by comparing the difference in
ean change between the pravastatin and the placebo group
fter two-year treatment by analysis of covariance, in which
ndependent variables were treatment and baseline levels.
earson and Spearman correlations were used to summarize
he relationship between OxLDL markers and Lp(a) and
RP at baseline and after two years.
Variables with a skewed distribution were log-
ransformed before the analysis. A p level of 0.05 was
onsidered statistically significant (two sided). Statistical
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nstitute, Cary, North Carolina).
ESULTS
aseline clinical characteristics. The baseline demo-
raphics and physical characteristics of the study group were
escribed previously (2) and were not significantly different
etween children with FH in the pravastatin group and the
lacebo group. There were no significant differences in those
hildren with (n  178) and without (n  36) available blood
amples for OxLDL measurements. Children with FH did not
iffer from unaffected siblings with regard to baseline charac-
eristics, except for mean carotid IMT, age, and lipid levels
Table 1). A molecular diagnosis of FH was obtained in
5% of the children. None of the children with FH suffered
rom cardiovascular disease or had any cardiovascular symp-
oms. At baseline, 5.6% of the FH children had tendinous
anthomas at physical examination and 6.1% smoked reg-
larly. Smoking status (p  0.80) as well as clinical
haracteristics (p  0.55) were equally distributed between
oth treatment groups.
aseline OxLDL markers and lipoprotein levels in the
tudy group and in unaffected siblings. The baseline lipid
evels, apoB, CRP, OxPL/apoB, apoB-IC, and MDA-
DL autoantibodies were similar between the pravastatin
nd placebo groups. However, the Lp(a) levels were bor-
able 1. Baseline Characteristics, OxLDL Markers, Lipids, and L
FH
Pravastatin, n  90 Pla
ge 12.9 (3.0) 12
ender, male (%) 48 (53) 4
ipids and lipoproteins
Total cholesterol 303.1 (58.9) 301
HDL cholesterol 47.2 (10.1) 49
LDL cholesterol 238.8 (56.2) 237
Triglycerides 69.5 (51.2–114.5) 62
apoB 140.4 (36.1) 140
Lp(a) 8.1 (4.4–20.5) 7
sCRP 0.03 (0.01–0.10) 0.0
arotid IMT 0.498 (0.056) 0.49
xLDL markers
OxPL/apoB 2,473 (1,615–6,610) 2,26
Autoantibodies to MDA-LDL
IgG 2,497 (1,682–3,904) 2,29
IgM 16,337 (6,856) 16,19
Immune complexes
Total IgG apoB-IC 3,255 (2,173–4,782) 3,28
Total IgM apoB-IC 4,919 (3,247) 5,00
IgG IC/apoB 2,344 (1,742–3,250) 2,30
IgM IC/apoB 3,537 (2,835) 3,55
or total IgG and IgM apoB-IC units are relative light units (RLU, mg/dl) 103. Fo
otal cholesterol, HDL-C, LDL-C, triglycerides, apoB, and Lp(a) levels are in mg/d
re given in mean and standard deviation or median and interquartile range. To conv
mol/l, divide by 88.57. *p value t test for pravastatin group vs. placebo group; †p val
n SAS procedure GENMOD for FH vs. siblings. ‡hsCRP values were available fro
apoB  apolipoprotein B-100; FH  familial hypercholesterolemia; HDL 
omplexes; Ig  immunoglobulin; IMT  intima-medial thickness; LDL  low-de
ow-density lipoprotein; OxPL  oxidized phospolipid.erline higher in the pravastatin group (median levels 8.1 vs. c.4 mg/dl; p  0.049) (Table 1). The unaffected siblings, as
xpected, had lower levels of all lipoproteins, except Lp(a),
hich was similar, and lower levels of CRP and carotid
MT (Table 1) (4).
Interestingly, compared with their unaffected siblings,
hildren with FH had significantly lower levels of OxPL/
poB (p  0.001) and IgG IC/apoB (p  0.016) but
igher levels of total IgG apoB-IC, total IgM apoB-IC,
nd IgM MDA-LDL autoantibodies (p  0.001 for all)
Table 1). No significance differences were present in
gM IC/apoB, IgG MDA-LDL autoantibodies, or
p(a).
ffect of pravastatin on absolute changes in OxLDL
arkers and Lp(a) in children with FH. As previously
escribed, total cholesterol, LDL-C, and apoB levels de-
reased significantly in the pravastatin group (p  0.001 for
ll) after two years, whereas no significant change occurred
n the placebo group (Table 2) (2).
The absolute median values of OxPL/apoB increased
ignificantly in the placebo group from baseline to 2-year
ollow-up (p  0.003) (Table 2). The only intervention in
his group was an emphasis on a low-fat diet. Such a change
n OxPL/apoB in response to low-fat diets was previously
bserved (17). In subjects on pravastatin, there was a greater
ncrease in the OxPL/apoB ratio from baseline to 2 years
p  0.001) (Table 2), which was significantly higher
rotein Levels in FH Children and Unaffected Siblings
Siblings, n  78 p Value†, n  88 p Value*
) 0.985 14.1 (3.0) 0.001
) 0.640 42 (54) 0.359
.6) 0.787 168.1 (25.3) 0.001
.1) 0.163 55.7 (12.6) 0.001
.1) 0.865 97.8 (23.0) 0.001
.2–92.6) 0.019 53.1 (41.6–74.4) 0.015
.6) 0.918 80.7 (16.4) 0.001
–13.2) 0.049 6.7 (4.5–22.8) 0.422
1–0.07) 0.088 0.01 (0.01–0.03)‡ 0.004
49) 0.526 0.480 (0.048) 0.024
62–3,920) 0.430 3,864 (2,847–11,557) 0.001
02–3,307) 0.160 2,589 (1,608–4,134) 0.761
32) 0.885 13,534 (5,273) 0.001
15–4,235) 0.811 2,342 (1,554–3,141) 0.001
58) 0.853 2,905 (1,419) 0.001
93–2,972) 0.910 2,871 (2,154–3,407) 0.016
29) 0.945 3,691 (1,717) 0.518
L/apoB IgG and IgM IC/apoB and autoantibodies to MDA-LDL units are in RLU.
RP levels are given in mg/l. Carotid IMT is given in mm. Age is given in yrs. Values
al-C, HDL-C, and LDL-C in mmol/l, divide by 38.67. To convert triglycerides in
logistic regression analysis adjusted for family using generalized estimating equations
ly 16 siblings.
ensity lipoprotein; hs-CRP  high sensitivity C-reactive protein; IC  immune
iporotein; Lp(a)  lipoprotein (a); MDA  malondialdehyde; OxLDL  oxidizedipop
cebo
.9 (2.9
5 (51
.0 (45
.4 (11
.5 (46
.4 (41
.0 (25
.4 (2.8
2 (0.0
3 (0.0
6 (1,3
9 (1,5
2 (6,5
5 (2,5
4 (2,8
9 (1,8
7 (1,7
r OxP
l. hsC
ert tot
ue for
m on
high-dompared with placebo (p  0.003) (Table 2). We previ-
ously
observed
sim
ilar
findings
in
adult
patients
w
ith
A
C
S
in
response
to
atorvastatin
(16).
T
he
total
IgG
apoB
-IC
decreased
significantly
in
both
the
placebo
(p

0.001)
(T
able
2)
and
pravastatin
groups
(p

0.001)
(T
able
2)
but
w
as
significantly
low
er
in
the
pravastatin
group
(p

0.001)
com
pared
to
placebo
(T
able
2).T
he
totalIgM
apoB
-IC
only
decreased
in
the
pravasta-
tin
group
(p

0.001)
com
pared
to
placebo
(T
able
2).T
he
IgG
IC
/apoB
decreased
significantly
in
both
the
controland
pravastatin
groups
(T
able
2).
T
here
w
ere
no
significant
differences
betw
een
the
pravastatin
and
placebo
groups
in
IgM
IC
/apoB
orIgG
and
IgM
M
D
A
-L
D
L
autoantibodies.
Interestingly,
absolute
m
edian
values
of
L
p(a)
also
in-
creased
significantly
in
the
pravastatin
arm
(8.1
[interquar-
tile
range
4.4
to
20.5]
to
10.5
[5.9
to
22.1];p

0.001)
but
notin
the
controlgroup.A
n
increase
in
L
p(a)levelsw
asalso
docum
ented
previously
in
response
to
low
-fat
diets
and
atorvastatin
(16,17).
In
the
entire
FH
cohort,
a
strong
correlation
w
as
noted
betw
een
O
xP
L
/apoB
and
L
p(a)
at
baseline
(r

0.84;p

0.001)and
tw
o
years
(r

0.92;p

0.001)
(Fig.
1).
T
his
relationship
w
as
also
true
of
the
unaffected
siblings
(r

0.89;p

0.001).
Table 2. Baseline and Two-Year Treatment Mean Levels of Lipids, Lipoproteins, and OxLDL Markers in Children With FH
Placebo (n  88)
Differences (95% CI) p Value†Baseline (SD) 2 Yrs (SD) Value*
Lipids and lipoproteins
Total cholesterol 301.0 (45.6) 300.4 (56.0) 0.001 53.7 (71.2 to 36.1) 0.001
HDL cholesterol 49.4 (11.1) 49.9 (10.5) 0.001 3.0 (0.3 to 5.8) 0.073
LDL cholesterol 237.5 (46.1) 236.5 (56.2) 0.001 55.6 (72.8 to 38.3) 0.001
Triglycerides 62.4 (41.2–92.6) 61.1 (39.9–85.9 0.044 9.5 (22.5 to 3.6) 0.756
apoB 140.0 (25.6) 139.8 (31.4) 0.001 26.1 (33.7 to 18.5) 0.001
Lp(a) 7.4 (2.8–13.2) 7.4 (2.7–15.3) 0.001 1.3 (0.1 to 2.4) 0.061
OxLDL markers
OxPL/apoB 2,266 (1,362–3,920) 2,658 (1,587–4,6 0.001 1,970 (818 to 3,123) 0.003
Autoantibodies to MDA-LDL
IgG 2,299 (1,502–3,307) 2,385 (1,527–3,2 0.209 51 (537 to 435) 0.976
IgM 16,192 (6,532) 16,213 (6,263) 0.314 512 (1,812 to 787) 0.491
Immune complexes
Total IgG apoB-IC 3,285 (2,515–4,235) 2,881 (2,158–3,8 0.001 612 (1,090 to 133) 0.001
Total IgM apoB-IC 5,004 (2,858) 5,279 (3,745) 0.001 1,327 (1,970 to 685) 0.001
IgG IC/apoB 2,309 (1,893–2,972) 2,096 (1,691–2,8 0.013 56 (246 to 358) 0.298
IgM IC/apoB 3,557 (1,729) 3,733 (2,184) 0.138 332 (692 to 29) 0.085
Notes as in Table 1. *p value within treatment group t test for change after two years; †p v
CI  confidence interval; other abbreviations as in Table 1.
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Pravastatin (n  90)
p Value† Baseline (SD) 2 Yrs (SD) p
0.837 303.1 (58.9) 246.8 (62.1) 
0.616 47.2 (10.1) 50.7 (12.1)
0.767 238.8 (56.2) 180.9 (59.7) 
) 0.845 69.5 (51.2–114.5) 67.3 (42.5–100.0)
0.882 140.4 (36.1) 114.0 (39.8) 
0.735 8.1 (4.4–20.5) 10.5 (5.9–22.1) 
68) 0.003 2,473 (1,615–6,610) 3,863 (2,052–11,933) 
51) 0.735 2,497 (1,682–3,904) 2,365 (1,815–3,844)
0.966 16,337 (6,856) 159,001 (6,593)
91) 0.001 3,255 (2,173–4,782) 2,342 (1,686–3,934) 
0.310 4,919 (3,247) 3,936 (2,769) 
24) 0.001 2,344 (1,742–3,250) 2,281 (1,726–3,050)
0.273 3,537 (2,835) 3,114 (1,847)
alue for differences after two years between treatment groups (ANCOVA).
Figure
1.
R
elationship
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oxidized
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)
and
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(a)
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in
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cohort
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May 2, 2006:1803–10 Oxidized LDL in Children Treated With Statinsffect of pravastatin on relative changes in OxLDL
arkers and Lp(a). As compared with placebo, pravastatin
ignificantly increased OxPL/apoB (absolute mean increase
f 19.4%; p  0.028) and Lp(a) (absolute mean increase of
1.2%; p  0.044) but significantly decreased total IgM
poB-IC and total IgG apoB-IC (Fig. 2). No significant
hanges were noted in IgG and IgM apoB-IC or IgG and
gM MDA-LDL autoantibodies from baseline to two
ears.
elationship among OxLDL markers, CRP, and carotid
MT. In the entire FH cohort, OxPL/apoB correlated
eakly with IgG MDA-LDL (r 0.17; p 0.023) but not
ith other OxLDL markers or lipid parameters. The IgM
DA-LDL autoantibodies correlated with IgM apoB-IC
r  0.62; p  0.001), and similarly IgG MDA-LDL
utoantibodies correlated with IgG apoB-IC (r 0.34; p
.001). An inverse but weak correlation was noted between
DL-C and IgG MDA-LDL (r  0.15; p  0.0049). In
ontrast, in the unaffected siblings, there was a positive
orrelation between LDL-C and IgG MDA-LDL (r 
.29; p 0.013). There was a modest positive correlation of
sCRP with OxPL/apoB (r  0.16; p  0.038) and Lp(a)
r  0.17; p  0.025) at baseline in the FH group but not
igure 2. Mean percent change (with 95% confidence intervals [CIs]) in O
bbreviations as in Table 1.ith the other OxLDL markers. None of the OxLDL Iarkers, Lp(a), or hsCRP predicted the baseline or the
hange in carotid IMT following pravastatin treatment.
ISCUSSION
his study demonstrates that children with FH have signifi-
antly higher concentrations of apoB-IC and IgM MDA-
DL autoantibodies but lower levels of OxPL/apoB than
naffected siblings. Furthermore, pravastatin treatment of
hildren with FH decreased total levels of apoB-associated
mmune complexes but actually increased OxPL/apoB lev-
ls, in parallel with similar increases in Lp(a) levels. Con-
istent with our previous hypothesis, these changes may
epresent mobilization of OxPL into the circulation follow-
ng treatment with statins (16) and low-fat diets (17). It also
uggests up-regulation of Lp(a) levels by statins and/or by
xPL which have been shown to be strongly bound by
p(a) (8,13,15,16,18), as opposed to other apoB-containing
ipoproteins.
Children with FH are characterized by elevated LDL-C
evels at birth and more rapid progression to clinical CVD
s they become young adults compared to normocholester-
lemic children. Even in the pediatric period, they exhibit
vidence of subclinical atherosclerosis with increased carotid
markers from baseline to two years in the placebo and pravastatin groups.MT (3,4) and endothelial dysfunction compared with
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Oxidized LDL in Children Treated With Statins May 2, 2006:1803–10imilar-aged controls (1,19,20). Recent statin trials in chil-
ren with FH demonstrated significant decreases in
DL-C levels without apparent adverse effects over one- to
wo-year treatment periods (1,4,21,22). Pravastatin has
een shown to induce carotid IMT regression (4) and
imvastatin to improve endothelial function in children with
H (1,23). In addition, oral antioxidant vitamins C (500
g/day) and E (400 IU/day) have also been shown to
mprove brachial flow-mediated dilatation in children with
H (24) but, interestingly, did not affect the levels of the
ame OxLDL markers, as measured in this study, nor other
arkers of oxidation such as F2-isoprostanes.
Oxidized LDL is both immunogenic (25,26) and proin-
ammatory (27,28). In adults, a significant amount of data
xist on the role of autoantibodies to OxLDL and their
mpact on atherogenesis. Although results are equivocal, it
ppears that IgG autoantibodies are positively associated
ith various manifestations of CVD (29), whereas IgM
utoantibodies may be atheroprotective (30). However,
lthough they may play a role in modifying atherogenesis, it
as not been conclusively established if autoantibodies to
xLDL have independent predictive value as biomarkers
or CVD above and beyond traditional cardiovascular risk
actors. In addition, data are now emerging from several
aboratories that circulating OxLDL, measured by different
ntibodies, is associated with clinical and angiographic
VD and plaque disruption as noted in ACS and percuta-
eous coronary intervention (PCI) (7,9–14).
A major limitation in this field is the scarcity of prospec-
ive studies, which limits our understanding of the role of
xLDL in the development of CVD. In addition, although
hese measures are clearly interrelated, most studies do not
easure circulating OxLDL, immune complexes, and
xLDL autoantibodies in the same dataset, which would
rovide a more complete assessment and a better definition
f their role in atherogenesis. In children, particularly in
hose with FH where a clinical imperative is present to
dentify mechanisms of disease progression to initiate pre-
entative measures early in the disease process, similar
nformation is not available.
aseline levels of OxLDL markers in children with FH
nd unaffected siblings. To our knowledge, this study is
he first to show that children with FH are characterized by
igher levels of apoB-IC and IgM MDA-LDL autoanti-
odies and lower levels of OxPL/apoB than their unaffected
iblings, even after adjustment for age. The higher levels of
poB-IC and MDA-LDL autoantibodies are potentially
ttributed to immunologic responses to the presence of
xLDL in the vessel wall and possibly to smaller quantities
f OxLDL in the circulation. Consistent with this, it has
een shown that aortas from human fetuses, in whom the
others were hypercholesterolemic, contain OxLDL even
efore monocyte recruitment (31), suggesting that OxLDL
s present a priori in early human lesions before inflamma-
ory components. pInterestingly, OxPL/apoB levels were lower at baseline in
he children with FH than in unaffected siblings. This may
eflect the fact that the pool of apoB was larger, but the
xPL levels similar, in children with FH than in unaffected
iblings. We have documented previously that the majority
f OxPL resides on Lp(a) (8,13,15,16,18). Because Lp(a)
evels were similar in both groups at baseline, this may
imply be reflected by a lower OxPL/apoB ratio in children
ith FH. Another possibility is generation of immune
omplexes as a mechanism of reduced OxPL/apoB levels,
s implied by higher levels of apoB-IC in children with
H. In adults, it has been shown that a weak but
ignificant inverse correlation exists between OxLDL
utoantibodies and OxLDL levels, measured by antibody
LH3, which binds a similar epitope as antibody E06
32). One may also postulate that the lower OxPL/apoB
atio occurs because of enhanced deposition of OxPL in
he artery wall. Further study is needed to understand the
nderlying mechanisms of these observations.
xLDL markers in response to pravastatin in children
ith FH. The OxPL/apoB levels strongly correlate with
he presence and extent of angiographic coronary artery
isease (8) and are increased in ACS (13), immediately
ollowing PCI (15), and, interestingly, in response to
torvastatin and low-fat diets (16,17). In the Myocardial
schemia Reduction With Aggressive Cholesterol Lowering
MIRACL) study (16), we evaluated the role of oxidized
hospholipids present on apolipoprotein B-100 (OxPL/
poB) in response to high-dose atorvastatin and showed
hat the OxPL/apoB ratio was significantly increased in
esponse to 80 mg atorvastatin, in concert with a propor-
ional increase in Lp(a) levels. The reasons for the increase
n OxPL/apoB and Lp(a) in response to statins (or low-fat
iet) is not yet determined, but several other statin studies
ave also suggested small and even moderate increases in
p(a) levels (33–36). For example, Kostner et al. (34)
howed a dose-response in the increase in Lp(a) levels with
ovastatin (0 mg: no change; 20 mg: 27%; 40 mg: 23%;
0 mg: 29%; 80 mg: 34%). We have shown that OxPL
re preferentially bound to Lp(a) as opposed to other
poB-containing lipoproteins, both bound to apolipopro-
ein (a) (18) as well as in the lipid phase of Lp(a) (Tsimikas
nd Witztum, unpublished observations). Consistent with
he observations in this study, atorvastatin was also shown to
ignificantly decrease total IgG and IgM apoB-IC com-
ared with placebo in the MIRACL study.
Based on the above studies, we have postulated that Lp(a)
ay function to bind, transport, and potentially detoxify
xPL that are generated through oxidative stress (8,16).
he reason for this increased OxPL/apoB in response to
tatins, which may seem paradoxical with other beneficial
roperties of statins, has not been fully elucidated but is
learly now a consistent finding in response to atorvastatin
nd pravastatin as well as in response to low-fat diets,
onditions where one might postulate a flux of OxPL from
eripheral storage sites, such as the vessel wall. For example,
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May 2, 2006:1803–10 Oxidized LDL in Children Treated With Statinshe control group of this study, after counseling on an
merican Heart Association step II diet (4) also had
ncreases in OxPL/apoB and Lp(a) but less of an increase
han the pravastatin group. This is consistent with the data
y Silaste et al. (17) showing a median increase in OxPL/
poB and Lp(a) by approximately 25% and 9%, respectively,
fter 5 weeks of medically supervised low-fat diets. The
xplanations for these findings still need to be determined.
ne possibility is that Lp(a) is up-regulated in response to
tatins or low-fat diet and binds OxPL that may be derived
rom peripheral sources, such as the vessel wall, tendon
anthomas, the reticuloendothelial system, or even remote
ites of inflammation. Consistent with this, we have also
hown an increase in OxPL/apoB in nonatherogenic mice
ransgenic for human Lp(a) (37). We have recently shown
hat placing LDLR/ mice with preexisting atherosclero-
is on low-fat diets results in a marked reduction in OxPL
mmunostaining of atherosclerotic plaques, even before
omplete lesion regression or cholesterol removal from the
essel wall, suggesting that efflux of OxPL from the vessel
all is a very early phenomenon during atherosclerosis
egression (38). Additional animal data from our laboratory
Tsimikas and Witztum, unpublished observations) in sev-
ral atherosclerotic animal models with or without Lp(a),
lso suggests that with increased plasma OxPL/apoB levels
ollowing low-fat diets there are concomitant reductions of
xPL immunostaining in the vessel wall, suggesting an
fflux of OxPL from the vessel wall to the circulation.
In the current study, none of the OxLDL markers, Lp(a),
r hsCRP predicted change in carotid IMT. There are
everal potential explanations for these findings. First, in
his group of subjects the LDL-C levels were exceedingly
igh, even in the group treated with pravastatin (2-year
DL-C results were 237 mg/dl in the placebo and 181
g/dl in the pravastatin arm), which may have been the
rimary driver of increased carotid IMT. Second, the
ollow-up period was only two years, which may not have
een long enough to see a significant relationship in the
hange in OxLDL markers and carotid IMT. In fact, we
ave shown that in adults from the general community
anging from 40 to 79 years of age derived from the Bruneck
Italy) population (39) that OxLDL-E06 predicts the pres-
nce of carotid atherosclerosis at baseline as well as the
-year rate of progression (40). This is consistent with our
ecent observation that OxLDL-E06 levels are independent
redictors of angiographically determined coronary athero-
clerosis (8). Third, the wide age range of the subjects (from
to 18 years of age) may have introduced unmeasured
ariables in the progression of IMT and its relationship to
xLDL markers. Fourth, the IMT thickness at this age
roup was quite modest at 0.5 mm, which may not be
ensitive enough to detect a relationship between OxLDL
nd vessel wall changes. Finally, it is possible that these
xLDL measures are simply not predictive of carotid IMT
t this very early stage of atherogenesis. From a clinical
erspective, although this study provides unique and inter-
1sting pathophysiologic insights into the role of OxLDL in
hildren with FH, further studies are needed to fully
valuate their potential clinical value.
In summary, this study suggests that children with FH
re characterized by unique changes in OxLDL markers
hich suggest immune activation to OxLDL. Furthermore,
ravastatin treatment decreased total levels of apoB-
ssociated immune complexes but actually increased OxPL/
poB levels, in parallel with similar increases in Lp(a) levels,
hich may represent a potential novel mechanism of mo-
ilization and clearance of OxPL. Additional long-term
tudies in children are needed to establish whether these
arkers ultimately predict cardiovascular outcomes.
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ascular Medicine Program, University of California San Diego,
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